About JENSCARE-B Company

Ningbo Jianshi Technology Co., Ltd. is a medical device company based in China, dedicated to developing interventional products for the treatment of structural heart disease. The company was established in China in November 2011. Since then, we have developed a range of treatment solutions for different types of structural heart disease, including tricuspid valve disease, aortic valve disease, mitral valve disease, and heart failure. Our core product, LUX-Valve, has the potential to treat severe tricuspid valve reflux, and according to Frost & Sullivan data, given that LUX-Valve is the world's first product under development to complete confirmatory clinical trial enrolment, it is expected that it will be one of the first transcatheter tricuspid valve replacement products approved for commercialization in the world. Furthermore, according to Frost & Sullivan's data, LUX-Valve was recognized by the US Food and Drug Administration as a “breakthrough medical device” under the Breakthrough Medical Device Program in November 2021, making it the first domestic self-developed medical device to receive this certification in the field of heart valve disease treatment. Another of our core products, Ken-Valve, is designed to treat severe aortic valve regurgitation (or aortic stenosis). It is expected to meet the needs of more patients, far greater than the transcatheter aortic valve replacement system whose only indication is aortic stenosis. We are also developing eight other products with advanced technology, including (i) JensClip, an innovative transcatheter mitral valve repair clamping system with many unique designs that make it stand out from other transcatheter mitral valve repair systems on the market; (ii) MitraPatch, an innovative transcatheter mitral valve repair product that uses valve repair technology to repair mitral valves; and a variety of advanced products under development for different types of valvular heart disease and heart failure.